Forslund Anna, Haraldsson Erik, Holmberg Erik, Naredi Peter, Rizell Magnus
Transplant Institute, Sahlgrenska University Hospital, 41345, Gothenburg, Sweden.
Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
Surg Endosc. 2025 Feb;39(2):991-1001. doi: 10.1007/s00464-024-11449-8. Epub 2024 Dec 13.
In biliary cancer, the indication of endoscopic intervention might be diagnostic as well as therapeutic, in the latter situation with the aim to relieve biliary obstruction e.g. by stenting. Our aim was to investigate the use of endoscopic biliary interventions during the diagnostic workup of biliary cancers in a national cohort, and to evaluate their complications, especially cholangitis and pancreatitis.
This is a registry-based study of national cohort of patients with biliary cancers in Sweden 2010-2020. The use of endoscopic retrograde cholangiopancreatography (ERCP) during the diagnostic work up period before treatment onset, and risk of complications were evaluated in patients with gallbladder cancer, intrahepatic-, perihilar- and distal cholangiocarcinoma. The risk of complications was compared depending on age, sex, comorbidity, in relation to stage and curative intent, endoscopy unit size, and with relation to survival.
Forty percent of the patients with biliary cancer underwent ERCP during the diagnostic workup, with variations depending on diagnosis. There was a 20% overall risk of periprocedural complications, a 9% risk of post-ERCP-pancreatitis (PEP), and a 6% risk of cholangitis. Increasing tumor stage did not increase risk, nor did comorbidity. The complication rates were slightly higher for younger patients and those undergoing curative treatment. For perihilar cholangiocarcinoma (pCCA) treated with curative intention, the risk of periprocedural complications was as high as 30.7%. No association between post-ERCP complications and survival was found.
Irrespective of type of biliary cancer, ERCP is frequently used during diagnostic workup. The complication risk indicates that primary biliary cancers are complication prone, regardless of stage. Notably the risk of complications was the highest for younger patients with low comorbidity scores, as well as for patients undergoing curatively aiming treatment.
在胆管癌中,内镜干预的指征可能具有诊断和治疗双重作用,在后一种情况下,目的是通过支架置入等方式缓解胆管梗阻。我们的目的是调查在一个全国性队列中胆管癌诊断检查期间内镜胆管干预的使用情况,并评估其并发症,尤其是胆管炎和胰腺炎。
这是一项基于登记的对2010 - 2020年瑞典全国胆管癌患者队列的研究。在治疗开始前的诊断检查期间,对胆囊癌、肝内胆管癌、肝门周围胆管癌和远端胆管癌患者使用内镜逆行胰胆管造影(ERCP)的情况以及并发症风险进行了评估。根据年龄、性别、合并症、分期和治愈意图、内镜检查单位规模以及生存情况比较了并发症风险。
40%的胆管癌患者在诊断检查期间接受了ERCP,具体比例因诊断而异。围手术期并发症的总体风险为20%,ERCP后胰腺炎(PEP)的风险为9%,胆管炎的风险为6%。肿瘤分期增加并未增加风险,合并症也未增加风险。年轻患者和接受根治性治疗的患者并发症发生率略高。对于接受根治性治疗的肝门周围胆管癌(pCCA),围手术期并发症风险高达30.7%。未发现ERCP后并发症与生存之间存在关联。
无论胆管癌类型如何,ERCP在诊断检查期间经常使用。并发症风险表明,原发性胆管癌无论处于何阶段都容易发生并发症。值得注意的是,合并症评分低的年轻患者以及接受根治性治疗的患者并发症风险最高。